FibroGen, Inc (NASDAQ:FGEN) – Investment analysts at William Blair lifted their Q3 2018 earnings per share estimates for FibroGen in a research note issued to investors on Thursday. William Blair analyst A. Hsieh now anticipates that the biopharmaceutical company will earn $1.00 per share for the quarter, up from their previous forecast of $0.86. William Blair has a “Outperform” rating on the stock.

WARNING: “Q3 2018 EPS Estimates for FibroGen, Inc (FGEN) Increased by Analyst” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/11/11/q3-2018-eps-estimates-for-fibrogen-inc-fgen-increased-by-analyst.html.

A number of other equities research analysts also recently issued reports on the stock. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective on the stock. in a research note on Friday, July 21st. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Stifel Nicolaus boosted their price target on shares of FibroGen from $38.00 to $80.00 and gave the company a “buy” rating in a research note on Tuesday, August 8th. Jefferies Group LLC restated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday, August 8th. Finally, Citigroup Inc. lifted their price objective on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a report on Tuesday, August 8th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $65.67.

Shares of FibroGen (FGEN) traded down $1.13 during mid-day trading on Friday, reaching $47.12. 754,500 shares of the company’s stock were exchanged, compared to its average volume of 626,675. The company has a quick ratio of 6.21, a current ratio of 10.83 and a debt-to-equity ratio of 0.16. FibroGen has a 12-month low of $19.25 and a 12-month high of $60.15.

In related news, insider K Peony Yu sold 15,000 shares of the stock in a transaction that occurred on Wednesday, October 4th. The stock was sold at an average price of $60.00, for a total value of $900,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the stock in a transaction that occurred on Thursday, August 17th. The shares were sold at an average price of $40.74, for a total value of $81,480.00. Following the completion of the sale, the director now directly owns 30,000 shares of the company’s stock, valued at approximately $1,222,200. The disclosure for this sale can be found here. In the last three months, insiders have sold 428,118 shares of company stock worth $22,355,896. Corporate insiders own 14.90% of the company’s stock.

A number of hedge funds have recently bought and sold shares of the business. New York State Common Retirement Fund grew its stake in shares of FibroGen by 24.0% in the second quarter. New York State Common Retirement Fund now owns 67,700 shares of the biopharmaceutical company’s stock valued at $2,187,000 after buying an additional 13,099 shares in the last quarter. FMR LLC lifted its holdings in FibroGen by 96.9% during the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock worth $107,753,000 after buying an additional 1,641,423 shares during the last quarter. Prudential Financial Inc. lifted its holdings in FibroGen by 9.6% during the 2nd quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock worth $14,496,000 after buying an additional 39,430 shares during the last quarter. Principal Financial Group Inc. increased its position in shares of FibroGen by 0.4% during the first quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock worth $3,354,000 after purchasing an additional 504 shares in the last quarter. Finally, Citigroup Inc. increased its position in shares of FibroGen by 37.3% during the second quarter. Citigroup Inc. now owns 40,046 shares of the biopharmaceutical company’s stock worth $1,294,000 after purchasing an additional 10,876 shares in the last quarter. 47.47% of the stock is owned by institutional investors.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.